Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 8-K (Current Report)
Date of Report: May 12, 2026
Reporting Period: Three months ended March 31, 2026 (Q1 2026)
This filing announces the release of financial results for the first quarter of fiscal year 2026 and details a related conference call held on May 12, 2026. The specific financial data is contained in the press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text serves as a cover report referencing the press release (Exhibit 99.1) for detailed figures. Consequently, the filing text does not provide clear values for the following metrics:
- Revenue: Not stated in this document.
- Profit/Loss: Not stated in this document.
- Cash Flow: Not stated in this document.
- Margins: Not stated in this document.
- Debt and Liquidity: Not stated in this document.
Material Changes
The filing text does not provide specific comparative data or material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for year-over-year or quarter-over-quarter analysis.
Guidance, Outlook, and Risks
Management Commentary: The Company announced a conference call to discuss the results, but the text of the call or specific management commentary is not included in this 8-K summary.
Guidance and Outlook: No forward-looking guidance or outlook is provided in this document.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, net income, and cash flow figures for the quarter ended March 31, 2026.
- Verify year-over-year growth rates and margin trends in the press release.
- Check the conference call transcript (if available) for management's commentary on the results and future outlook.
- Confirm whether the press release includes updated financial guidance for the full fiscal year 2026.